Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study.

López-Cano C, Ciudin A, Sánchez E, Tinahones FJ, Barbé F, Dalmases M, García-Ramírez M, Soto A, Gaeta AM, Pellitero S, Martí R, Hernández C, Simó R, Lecube A

Diabetes1 Feb 2022Cited by 40 (Europe PMC)

PMID34737187DOI10.2337/db21-0688PepBankPUB-34737187

Source link PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide increased forced vital capacity more than placebo (change 5.2% of predicted).
In plain wordsIn adults with type 2 diabetes, liraglutide improved lung capacity more than placebo.
Peptide
Liraglutide
Outcome
IncreaseForced vital capacity (FVC)
Study
n = 76
Comparator
Placebo
Outcome group
Respiratory function · Respiratory
Studied dose
1.8 mg daily · 7 weeksAs given in this study (human).
Measurements
ΔFVC
5.2 % of predicted
liraglutide versus placebo
95% CI
0.8 to 9.6 % of predicted
ΔFVC
Source sentences
Summary
Liraglutide exerted a positive impact on forced vital capacity (FVC) in comparison with placebo (ΔFVC 5.2% of predicted [from 0.8 to 9.6]; P = 0.009).
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide was administered for 7 weeks (2 weeks of titration plus 5 weeks at 1.8 mg daily).
Summary · context
A double-blind, randomized, crossover, placebo-controlled clinical trial comprising 76 patients with a baseline forced expiratory volume in 1 s <90% of that predicted.
Report a problemFND-3473718701
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide did not change the other pulmonary variables versus placebo.
In plain wordsIn adults with type 2 diabetes, liraglutide did not change the other lung measures compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeOther pulmonary function variables
Study
n = 76
Comparator
Placebo
Outcome group
Respiratory function · Respiratory
Studied dose
1.8 mg daily · 7 weeksAs given in this study (human).
Source sentences
Summary
No differences in the other pulmonary variables were observed.
1 context sentence(design, population, supporting numbers)
Summary · context
A double-blind, randomized, crossover, placebo-controlled clinical trial comprising 76 patients with a baseline forced expiratory volume in 1 s <90% of that predicted.
Report a problemFND-3473718702
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, serum SP-D, a marker of alveolar-capillary barrier integrity, decreased with liraglutide treatment.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered a blood marker of lung barrier integrity.
Peptide
Liraglutide
Outcome
DecreaseSerum surfactant protein D (SP-D)
Study
n = 76
Outcome group
Respiratory function · Respiratory
Studied dose
1.8 mg daily · 7 weeksAs given in this study (human).
Source sentences
Summary
Participants under liraglutide treatment also experienced a decrease in serum SP-D (P = 0.038).
2 context sentences(design, population, supporting numbers)
Summary · context
Serum level of SP-D was used as a biomarker of alveolar-capillary barrier integrity.
Summary · context
A double-blind, randomized, crossover, placebo-controlled clinical trial comprising 76 patients with a baseline forced expiratory volume in 1 s <90% of that predicted.
Report a problemFND-3473718703
04HumanRandomized controlled trialMechanism
In adults with type 2 diabetes given liraglutide, the absolute change in FVC correlated with final serum SP-D (r = -0.313).
In plain wordsIn adults with type 2 diabetes on liraglutide, bigger lung capacity gains went with lower SP-D levels.
Peptide
Liraglutide
Outcome
Not applicableCorrelation of FVC change with final serum SP-D
Study
n: not reported in source
Outcome group
Respiratory function · Respiratory
Studied dose
1.8 mg daily · 7 weeksAs given in this study (human).
Measurements
r
−0.313
FVC change versus final SP-D, liraglutide group
Source sentences
Summary
The absolute change in FVC correlated with final serum SP-D in participants receiving liraglutide (r = -0.313, P = 0.036).
1 context sentence(design, population, supporting numbers)
Summary · context
A double-blind, randomized, crossover, placebo-controlled clinical trial comprising 76 patients with a baseline forced expiratory volume in 1 s <90% of that predicted.
Report a problemFND-3473718704
05HumanRandomized controlled trialMechanism
In stepwise multivariate regression, final serum SP-D independently predicted changes in FVC.
In plain wordsIn a statistical model, final SP-D level independently predicted the change in lung capacity.
Peptide
Liraglutide
Outcome
Not applicableFinal serum SP-D as predictor of FVC change
Study
n: not reported in source
Outcome group
Respiratory function · Respiratory
Studied dose
1.8 mg daily · 7 weeksAs given in this study (human).
Source sentences
Summary
Stepwise multivariate regression analysis showed that final serum SP-D independently predicted changes in FVC.
1 context sentence(design, population, supporting numbers)
Summary · context
A double-blind, randomized, crossover, placebo-controlled clinical trial comprising 76 patients with a baseline forced expiratory volume in 1 s <90% of that predicted.
Report a problemFND-3473718705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02889510

Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus

Lecube, Albert, M.D.n = 764 Oct 2016 to 16 Dec 2019

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 26 Feb 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.